361 related articles for article (PubMed ID: 31278209)
1. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
[TBL] [Abstract][Full Text] [Related]
2. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
3. Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Chu TH; Jung SH; Kim K; Lee JH; Mun YC; Bang SM; Yoon DH; Lee HS; Min CK; Lee JJ
Ann Hematol; 2022 Jun; 101(6):1217-1226. PubMed ID: 35445844
[TBL] [Abstract][Full Text] [Related]
4. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
5. Late Relapse of Multiple Myeloma with Testicular Plasmacytoma after Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature.
Wei ZL; Pan CM; Jiang YZ; Yan-Dai ; Huanguang LQ; Huang DP
Ann Clin Lab Sci; 2018 Jan; 48(1):120-125. PubMed ID: 29531008
[TBL] [Abstract][Full Text] [Related]
6. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
7. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
8. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.
Gagelmann N; Eikema DJ; Iacobelli S; Koster L; Nahi H; Stoppa AM; Masszi T; Caillot D; Lenhoff S; Udvardy M; Crawley C; Arcese W; Mariette C; Hunter A; Leleu X; Schipperus M; Delforge M; Pioltelli P; Snowden JA; Itälä-Remes M; Musso M; van Biezen A; Garderet L; Kröger N
Haematologica; 2018 May; 103(5):890-897. PubMed ID: 29419433
[TBL] [Abstract][Full Text] [Related]
9. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical features of multiple myeloma with paraosseous and extraosseous plasmacytoma in the era of novel drugs: a systemic review and meta-analysis.
Zhou D; Zhou X; Xu P; Chen B
Expert Rev Hematol; 2022 Apr; 15(4):369-374. PubMed ID: 35387532
[TBL] [Abstract][Full Text] [Related]
12. Late relapse of a light-chain myeloma as extramedullary plasmacytoma of the thyroid gland after second allogeneic stem-cell transplantation.
Ozdemir E; Bayraktar M; Sökmensüer C; Kir KM; Kansu E
Clin Transplant; 2009; 23(6):981-4. PubMed ID: 19689453
[TBL] [Abstract][Full Text] [Related]
13. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Goldman-Mazur S; Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Kumar SK
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e104-e111.e1. PubMed ID: 38135634
[TBL] [Abstract][Full Text] [Related]
14. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution.
Jiménez-Segura R; Rosiñol L; Cibeira MT; Fernández de Larrea C; Tovar N; Rodríguez-Lobato LG; Bladé E; Moreno DF; Oliver-Caldés A; Bladé J
Blood Cancer J; 2022 Sep; 12(9):135. PubMed ID: 36114167
[TBL] [Abstract][Full Text] [Related]
15. Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report.
Schols SE; Tick LL
J Med Case Rep; 2015 Feb; 9():37. PubMed ID: 25880694
[TBL] [Abstract][Full Text] [Related]
16. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.
Kremer M; Ott G; Nathrath M; Specht K; Stecker K; Alexiou C; Quintanilla-Martinez L; Fend F
J Pathol; 2005 Jan; 205(1):92-101. PubMed ID: 15586381
[TBL] [Abstract][Full Text] [Related]
17. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis.
Çiftçiler R; Göker H; Demiroğlu H; Aksu S; Sayınalp N; Haznedaroğlu İC; Malkan ÜY; Büyükaşık Y; Özcebe O
Turk J Haematol; 2020 Nov; 37(4):256-262. PubMed ID: 31833716
[TBL] [Abstract][Full Text] [Related]
19. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
[TBL] [Abstract][Full Text] [Related]
20. Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases.
Venkatesulu B; Mallick S; Giridhar P; Upadhyay AD; Rath GK
Eur Arch Otorhinolaryngol; 2018 Feb; 275(2):595-606. PubMed ID: 29224044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
